Member Info for OAPK20

See. Nada, Nothing, empty like their head

Only a duplicitous numptie would claim to have bought a share at .** 1.5p ** (Did ye, Aye) and hold all the way to a 40%_50% profit and expect people to believe they didn’t bank a profit.

Numpty behaviour right enough though.

What’s the odds on a “Top Sliced” “Free Ride” post next

That's all the House Pumpers have got.

No counter discussion or views

WINS | 2.10 | 300,000 | 2.70 | 300,000

That 2.3 bid withdrawn. Let's see where it closes.

@greatscopper 👀

#GSCU How many copper-gold porphyries could be hiding beneath Especularita? 🇨🇱

CEO Sam Garrett explains why the giant 75km²+ La Colorada lithocap could conceal multiple #copper-#gold systems

The next phase of exploration could be transformational ...

Hope that wasn’t the pump for the placing forward selling.

5 Orana Introduction Warrant Instrument

On 11 August 2025 the Company entered into a warrant instrument pursuant to which the Company has granted, conditional upon Admission, 75,000,000 warrants to Orana (“Orana Introduction Warrants”) to subscribe for new Ordinary Shares at an exercise price of £0.01 per ordinary share, subject to specific vesting criteria in connection with the Epassi Agreement. Of the 75,000,000 Orana Introduction Warrants, 25,000,000 vest when 300,000 Epassi clients subscribe for the MedPal app, a further 25,000,000 vest when 600,000 Epassi clients subscribe for the app and 25,000,000 vest when 900,000 Epassi clients subscribe for the app. The Orana Introduction Warrants are freely transferable and may be exercised at any time during the period of five years following Admission at a price of £0.01 per share.

Resistance is futile. Everything is there to push through except the material commercial opportunities under discussion need converting into mid/long term revenue generating contracts. Sooner the better.

For balance consider this. If wrong please provide a counter argument

Period-end cash £4,189 confirms near-zero cash before 17/04

placing. Material data point not previously available.

- Implied operating burn higher than prior estimate (£635k/month vs £567k/month).

- Funding behaviour score lifted by full disclosure of placing count since admission.

- Chairman departure announced 09/03

- Catalyst cost coverage falls below 1x — follow-on placing highly probable given runway, burn rate and forward investment requirement.

Weighted average exercise price - 2p

From yesterday. If you still think it’s rubbish. Fine.

Let’s see how the day finishes after news digest.

Spread is currently 7.692%.

RELATIVE VOLUME and BUY BLOCK volume end of day.

CONFIRMATION TRIGGER (COUNTER-BULLISH):

Close above 2.50p AND buy block volume >500k AND spread compresses below 8% AND RV recovers above 80%.

SCAP | 2.40 | 75,000 | 2.80 | 75,000

WINS | 2.40 | 75,000 | 2.70 | 75,000

SING | 2.20 | 75,000 | 2.70 | 75,000

PEEL | 2.20 | 75,000 | 2.70 | 75,000

CANA | 2.50 | 75,000 | 3.00 | 75,000

Verses Yesterday

SCAP | 1.90 | 75,000 | 2.60 | 75,000

WINS | 2.30 | 75,000 | 2.60 | 75,000

SING | 2.10 | 75,000 | 2.60 | 75,000

PEEL | 2.20 | 75,000 | 2.70 | 75,000

CANA | 2.20 | 75,000 | 2.70 | 75,000

Makes this all the more important along with current and future care home contracts.

Intangible asset - NHS and DSP licence

The primary asset acquired is the NHS community pharmacy contractor registration and distance selling pharmacy (DSP) licence. The Directors have assessed this intangible asset as having an indefinite useful life on the basis that the licence is not subject to a fixed contractual term, is renewable by the Group subject to ongoing regulatory compliance, and there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows for the Group.

The £340 million funding package and rollout of Independent Prescribing has been agreed with Community Pharmacy England.

Today’s announcement follows record investment over the past 2 years and a raft of measures to deliver more services to patients, including:

making the ‘morning-after pill’ available free of charge at pharmacies on the NHS for the first time ever, ending the postcode lottery women face in accessing the medicine and reducing inequalities

offering patients suffering depression convenient support at pharmacies when they are prescribed antidepressants, to boost mental health support in the community

cutting red tape and bureaucracy to give patients easier access to consultations, with more of the pharmacy team able to deliver a wider number of services such as medicines and prescriptions advice, Pharmacy First consultations for minor conditions, and carrying out blood pressure checks

boosting financial incentives for pharmacists to identify patients with undiagnosed high blood pressure.

boosting funding for medicine supply so patients have better access to the medicines prescribed for them.

Janet Morrison OBE, Chief Executive of Community Pharmacy England, said:

We welcome the agreement reached for community pharmacies in 2026/27, which includes an important commitment to a programme of reform for the sector.  It also opens the door to pharmacist prescribing – a first step towards making fuller use of their clinical expertise.

We hope these changes, accompanied by appropriate future investment, will help pharmacies to play an even greater role in supporting patients, improving access to care, and helping people get the advice and treatment they need in their communities.

Malcolm Harrison, Chief Executive, Company Chemists’ Association (CCA), said:

Today’s announcement recognises the longstanding and significant economic challenges facing the sector.

We welcome continued efforts to close the widely-acknowledged pharmacy funding gap.

Independent prescribing is a generational opportunity to expand the care that pharmacies can provide to patients. This announcement is the first step in realising this opportunity.

Under Pharmacy First, patients already have access to advice, over-the-counter treatments, and prescription only medicines under Patient Group Directions, which are the instructions for supplying or administering medicines.

This includes a range of minor health conditions affecting the ears, nose, throat, eyes and skin, among others. It provides rapid access for patients on their high street whilst taking pressure off GPs.

Community Pharmacies are crucial to the 10 Year Health Plan and shifting care out of hospital and into the community, as part of Neighbourhood Health Services.

From: Department of Health and Social Care, NHS England and Stephen Kinnock MP Published 29 May 2026

£340m pharmacy boost brings faster care to your high street

Patients to benefit from more services and treatments from their community pharmacy, as part of new deal.

Patients will see quicker access to treatments at their local pharmacy, avoiding GP referrals under new agreement

Government to roll out NHS-funded Independent Prescribing, bringing more care closer to home, as part of £340 million deal

Qualified pharmacists will deliver more NHS care on the high street, expanding successful Pharmacy

Patients across England will benefit from more services, treatments and better access to medicines from their local pharmacy under a new £340 million government-funded deal.

Under the new contractual framework, pharmacists who hold an Independent Prescribing qualification will be able to assess patients and prescribe medicines directly, building on the success of the Pharmacy First service. This delivers on-the-spot care for common conditions and gives patients access to a wider range of medicines.

The changes, which will be rolled out from Autumn 2026, will reduce the number of referrals back to GPs, boosting efficiency and improving both patient experience and outcomes. It will also lessen the burden on hospitals, as patients will be able to receive further treatment for common conditions from a qualified pharmacist in their community – avoiding the need to go to an urgent treatment centre or A&E.

Minister of State for Care, Stephen Kinnock said:

Through our landmark 10 Year Health Plan, we are making the most of our highly skilled pharmacists, while boosting access to services and giving patients more care right on their doorstep.

Independent Prescribing will play a major part in delivering this shift – easing pressures on GPs, cutting unnecessary red tape and helping patients get the right care closer to home.

Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England said:

Community pharmacies already play a vital role in delivering NHS care closer to home, and this agreement will make it easier for patients to get advice, treatment, and medicines through their local pharmacy.

Expanding independent prescribing will help make better use of the clinical expertise within our community pharmacy teams, helping patients get the right care in the right place while helping reducing pressure on other NHS

Its an overhang because they are still to be covered, therefor a future liquidity event, IF converted, which dilutes holders and adds supply to the market.

There's also the 4p warrants overhang capping expansion.

Bunsen you talk about placing overhang clearing. What's your thoughts on the 2p Warrant overhang ? In the money them.

Waiting for the GLP-1 pills getting the nod and commercial contracts being concluded before pulling the convert trigger ?

MammaC - No offence intended. But its literally in the RNS

MedPal AI (AIM: MPAL, FRA: Z1N), announces its interim results for the period ended 28 February 2026.

Chief Executive Officer's Statement

I am delighted to present MedPal AI plc's first interim results as an AIM-quoted company, covering the six months to 28 February 2026. This has been a period of rapid and disciplined execution of the Company's strategy since our admission to AIM in August 2025.

Make of it what you will. If you think it’s wrong please give a counter argument.

REVISED MONTHLY BURN (DISCLOSED INPUTS):

Admin costs H1: £3.36m / 6 months = £560k/month run rate

Marketing committed: £1.3m / 6 months = £217k/month

Revenue offset: £1.6m / 6 months = £267k/month inflow

Gross profit offset: £368,550 / 6 months = £61k/month inflow

March 2026 annualised pharmacy run rate £5m+ → £417k/month

revenue (improving)

H1 gross margin 23% blended; March margin >34%

NET CASH BURN (PROXY):

Admin £560k + Marketing £217k − Gross profit £61k (H1 base)

= ~£716k/month

Improving estimate using March data:

Admin £560k + Marketing £217k − Gross profit @ 34% of £417k

revenue (~£142k) = ~£635k/month

CONSERVATIVE BURN ESTIMATE: £635k/month (improving)

PRIOR BURN ESTIMATE: £567k/month

DELTA: +£68k/month (worse than prior)

RUNWAY (CONSERVATIVE):

£2,151,000 / £635,000 = 3.39 months as of mid-April

Less ~6 weeks elapsed to 29/05 = ~£950k consumed

Remaining cash 29/05 (EST): ~£1,200,000

Remaining runway from 29/05: £1,200,000 / £635,000 = 1.89 months

Only if you’re interested. (RV - Relative Volume)

BASE CASE (60%): Low-volume range compression. Range 2.30–2.50 confirmed across 12 sessions. Participation collapsing (RV 22%). Demand reliably appears at 2.50p (4 sessions) but cannot clear; support holds at 2.30p above 2.25p fail. Stock is coiled awaiting catalyst. Spread widening reflects low-volume MM behaviour. No directional resolution until catalyst delivery or runway pressure forces action.

Base Case (range compression) 60%

Counter-Bearish 25%

Counter-Bullish 15%

CONFIRMATION TRIGGER (BASE CASE):

Next sessions remain 2.30–2.50 with RV below 80% and neither close above 2.50p nor below 2.25p.

CONFIRMATION TRIGGER (COUNTER-BEARISH):

Close below 2.30p AND sell block volume >800k AND fail level 2.25p tested.

CONFIRMATION TRIGGER (COUNTER-BULLISH):

Close above 2.50p AND buy block volume >500k AND spread compresses below 8% AND RV recovers above 80%.

All fluff.

When the Accumulation is happening when the distribution is happening, compression, when the MM regimes are changing. Liquidity.

Much better reading.

Fluff just give the boost. But if you bought 10%, 20%, 30% stuck in the trap zone is the fluff enough to get out break even happy.

Or reading the tapes and being patient would’ve avoided that trap zone and buying when the MM distribution was happening instead buying when they are accumulating pre catalyst.

Mock it all you want Jimzi. If you’re not interested why do you feel the need to comment ? Didn’t say it was wrong though.

Strange that

Celeb endorsement of GLP-1 in US back in August 2025.

https://ro.co/

Serena Williams a fan, her husband an investor and on the board of Ro

(Serena did not disclose which specific medication she is on. Ro offers prescriptions for Ozempic, Wegovy, and Zepbound.)

https://www.womenshealthmag.com/health/a65819594/serena-williams-weight-loss-glp1-ro/

“Serena has since promoted the digital healthcare company Ro, which her husband Alexis Ohanian has invested in, as it provides access to prescription GLP-1 medications. One of her recent promos included appearing in a Super Bowl LX commercial, in which she said she is "moving better" and "feeling better" after starting the treatment.”

Just how big will the market be for GLP-1 the pills going forward with approvals.

https://ro.co/weight-loss/oral-wegovy/

If a fear of needles has kept you from taking Wegovy (semaglutide), we have good news. Oral Wegovy — aka the Wegovy pill — is officially available (and on Ro, no less!).

“ It’s also worth noting that the Wegovy pill may be just the start — other oral GLP-1s may soon be FDA-approved for weight loss and diabetes.

In fact, on April 1, 2026, Novo Nordisk’s competitor, Eli Lilly, received FDA approval for a GLP-1 pill for weight loss called Foundayo, i.e. brand-name orforglipron.

In a phase 3 clinical trial, adults with obesity or overweight who took Foundayo lost an average of 11.2% of their body weight after 72 weeks.

Another phase 3 trial showed that adults with obesity and type 2 diabetes lost an average of 5.1%–9.6% of their body weight over 72 weeks.

In a phase 2 trial, adults with obesity who took orforglipron lost an average of 9%–15% of their body weight after 36 weeks.

The development of an oral Wegovy (and, frankly, orforglipron or Foundayo) that’s equally as or close to as effective as injectable GLP-1s is exciting. This is largely because “pills are easier to take,” says Kevin Gendreau, MD, a board-certified obesity medicine physician.

“I’ve had many patients who dislike needles be hesitant to take these life-saving GLP-1 medications,” Dr. Gendreau says. “Pills have a broader acceptance and appeal in my opinion.”

Indeed, surveys show that when given the option, most people prefer an oral GLP-1 over an injection.”